Haemonetics (HAE) Return on Capital Employed (2010 - 2026)

Haemonetics' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 7.25% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 434.0% year-over-year to 7.25% in Q1 2026; TTM through Mar 2026 was 7.25%, a 434.0% decrease from a year earlier, with the FY2026 full-year figure at 7.32%, down 539.0% from the prior year.
• Return on Capital Employed retreated to 7.25% in Q1 2026 per HAE's latest filing, from 13.03% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 13.03% in Q4 2025 and bottomed at 2.76% in Q1 2022.
• The 5-year median for Return on Capital Employed is 8.6% (2022), against an average of 8.83%.
• Biggest YoY gain for Return on Capital Employed was 575 bps in 2022; the steepest drop was 890 bps in 2022.
• Year by year, Return on Capital Employed stood at 8.51% in 2022, then grew by 8 bps to 9.23% in 2023, then retreated by 14 bps to 7.93% in 2024, then surged by 64 bps to 13.03% in 2025, then slumped by 44 bps to 7.25% in 2026.
• Per Business Quant, the three latest HAE Return on Capital Employed figures stand at 7.25% (Q1 2026), 13.03% (Q4 2025), and 12.75% (Q3 2025).